Company intelligence / Profile preview

Maverix Dx

Menlo Park, California, United States

Ownership: Private
Development stage: Other

Overview

Maverix Dx is a diagnostic division established by Maverix Medical following the acquisition of Cirrus Bio, focusing on early detection and management of lung cancer through multiomics and NGS-based diagnostics. Maverix Dx leverages a cloud-based analytics platform for clinical reference labs and diagnostic developers, with an emphasis on scalable, regulatory-compliant workflows for genomic diagnostics. The division is led by experienced diagnostics executives and aims to expand its portfolio through internal development and strategic acquisitions.

Therapeutic areas: Oncology
Modalities: NGS-based diagnosticMultiomics diagnosticDevice
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Maverix Dx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Maverix Dx.

Explore the full profile